Akebia Therapeutics(AKBA)

Search documents
Akebia Therapeutics Announces Multiple Positive Business Updates
Prnewswire· 2025-01-13 13:00
Core Insights - Akebia Therapeutics has secured commercial supply contracts for Vafseo® (vadadustat), achieving nearly 100% coverage of dialysis patients in the U.S. [2][7] - Vafseo tablets are now shipping in the U.S. for adult patients with anemia due to chronic kidney disease (CKD) on dialysis for at least three months [2][4] - The company plans to initiate a Phase 3 trial in mid-2025 to potentially expand Vafseo's label to include treatment for late-stage non-dialysis CKD patients [3][4] Commercial Developments - Vafseo began shipping to dialysis centers on January 9, 2025, with broad access secured through agreements with dialysis organizations [7] - Market research indicates that 99% of nephrologists would consider prescribing Vafseo, with 75% intending to do so within six months of availability [7] - Akebia has engaged with the FDA regarding a Phase 3 cardiovascular outcome study for late-stage CKD anemia patients not on dialysis, expected to start in mid-2025 [3][7] Financial Outlook - The CEO of Akebia believes the company is entering a transformational year with the U.S. market availability of Vafseo, which could become a new standard of care for CKD patients [4] - The potential market opportunity for expanding Vafseo's label into the non-dialysis population is estimated to be multiple billion dollars in the U.S. [4] - Akebia expects its existing cash resources and cash from operations to be sufficient to fund its current operating plan for at least two years [7][8]
New Strong Sell Stocks for December 5th
ZACKS· 2024-12-05 11:51
Group 1 - Akebia Therapeutics, Inc. (AKBA) has been added to the Zacks Rank 5 (Strong Sell) List due to a 26.3% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Coca-Cola FEMSA, S.A.B. de C.V. (KOF) is also on the Zacks Rank 5 (Strong Sell) List, with a 10.5% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - DENTSPLY SIRONA Inc. (XRAY) has seen a 6.5% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days, leading to its inclusion in the Zacks Rank 5 (Strong Sell) List [2]
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
Prnewswire· 2024-11-25 13:00
Company Overview - Akebia Therapeutics, Inc. is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease [3] - The company was founded in 2007 and is headquartered in Cambridge, Massachusetts [3] Upcoming Event - John Butler, the Chief Executive Officer of Akebia, will participate in a Fireside Discussion at the 36th Annual Piper Sandler Healthcare Conference on December 3, 2024, at 10:30 AM EST [1] - The Piper Sandler Healthcare Conference will be held from December 3-5, 2024, in New York [3] Webcast Information - A webcast of the presentation will be available in the "Investors" section of Akebia's website for six months following the conference [2]
New Strong Sell Stocks for November 22nd
ZACKS· 2024-11-22 09:56
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:ATI Inc. (ATI) is a specialty manufacturing company. The Zacks Consensus Estimate for its current year earnings has been revised 5.2% downward over the last 60 days.Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 26.3% downward over the last 60 days.Alta Equipment Group Inc. (ALTG) is an equipment dealership company. The Zacks Consensus Estima ...
Q3 2024 Earnings: Hold Akebia Therapeutics
Seeking Alpha· 2024-11-20 20:31
Chris Lau is an individual investor and economist with 30 years of experience covering life science, technology, and dividend-growth income stocks. He has degrees in Microbiology and Economics. Chris runs the investing group DIY Value Investing where he shares his top stock picks of undervalued stocks with catalysts for upside, dividend-income recommendations with quant and payment calendar tracking, high upside plays, and research requests to help you become a better do-it-yourself investor. Learn more. To ...
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
Prnewswire· 2024-11-14 13:00
Akebia continues to publish important results of FO2CUS trial to further physicians' understanding of Vafseo® (vadadustat) CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has published the results of FO2CUS, an open-label study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible fa ...
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
Prnewswire· 2024-11-12 13:00
Group 1 - Akebia Therapeutics, Inc. is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease [1][2] - The company will have its CEO, John Butler, present at the Jefferies London Healthcare Conference on November 21, 2024, at 1:00 PM GMT [1] - A webcast of the presentation will be available for 30 days on Akebia's website [1] Group 2 - The Jefferies London Healthcare Conference is scheduled to take place from November 19-21, 2024, in London [2] - Akebia Therapeutics was founded in 2007 and is headquartered in Cambridge, Massachusetts [2]
Akebia Therapeutics(AKBA) - 2024 Q3 - Earnings Call Transcript
2024-11-07 18:59
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Business Officer Conference Call Participants Allison Bratzel - Piper Sandler Ed Arce - H.C. Wainwright Julian Harrison - BTIG Operator Good day and thank you for standing by. Welcome to the Akebia's Third Quarter 2024 Fi ...
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
ZACKS· 2024-11-07 14:15
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.06 per share when it actually produced a loss of $0.04, delivering a surprise of 33.33%.Over the last four quar ...
Akebia Therapeutics(AKBA) - 2024 Q3 - Quarterly Report
2024-11-07 12:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.00001 par value per share AKBA The Nasdaq Capital Market Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECT ...